|
1
|
Leppert W, Zajaczkowska R, Wordliczek J,
Dobrogowski J, Woron J and Krzakowski M: Pathophysiology and
clinical characteristics of pain in most common locations in cancer
patients. J Physiol Pharmacol. 67:787–799. 2016.
|
|
2
|
Grek CL, Rhett JM, Bruce JS, Ghatnekar GS
and Yeh ES: Connexin 43, breast cancer tumor suppressor: Missed
connections? Cancer Lett. 374:117–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Willebrords J, Crespo Yanguas S, Maes M,
Decrock E, Wang N, Leybaert L, da Silva TC, Veloso Alves Pereira I,
Jaeschke H, Cogliati B, et al: Structure, regulation and function
of gap junctions in liver. Cell Commun Adhes. 22:29–37. 2015.
View Article : Google Scholar
|
|
4
|
Hong X, Wang Q, Yang Y, Zheng S, Tong X,
Zhang S, Tao L and Harris AL: Gap junctions propagate opposite
effects in normal and tumor testicular cells in response to
cisplatin. Cancer Lett. 317:165–171. 2012. View Article : Google Scholar
|
|
5
|
Jensen R and Glazer PM:
Cell-interdependent cisplatin killing by Ku/DNA-dependent protein
kinase signaling transduced through gap junctions. Proc Natl Acad
Sci USA. 101:6134–6139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xiao J, Zhang G, Li B, Wu Y, Liu X, Tan Y
and Du B: Dioscin augments HSV-tk-mediated suicide gene therapy for
melanoma by promoting connexin-based intercellular communication.
Oncotarget. 8:798–807. 2017.
|
|
7
|
Kim YJ, Kim J, Tian C, Lim HJ, Kim YS,
Chung JH and Choung YH: Prevention of cisplatin-induced ototoxicity
by the inhibition of gap junctional intercellular communication in
auditory cells. Cell Mol Life Sci. 71:3859–3871. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Fu Y, Peng J, Wu D, Yu M, Xu C,
Wang Q and Tao L: Simvastatin-induced up-regulation of gap
junctions composed of connexin 43 sensitize Leydig tumor cells to
etoposide: An involvement of PKC pathway. Toxicology. 312:149–157.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sin WC, Aftab Q, Bechberger JF, Leung JH,
Chen H and Naus CC: Astrocytes promote glioma invasion via the gap
junction protein connexin43. Oncogene. 35:1504–1516. 2016.
View Article : Google Scholar
|
|
10
|
Plante I, Stewart MK, Barr K, Allan AL and
Laird DW: Cx43 suppresses mammary tumor metastasis to the lung in a
Cx43 mutant mouse model of human disease. Oncogene. 30:1681–1692.
2011. View Article : Google Scholar
|
|
11
|
He B, Tong X, Wang L, Wang Q, Ye H, Liu B,
Hong X, Tao L and Harris AL: Tramadol and flurbiprofen depress the
cytotoxicity of cisplatin via their effects on gap junctions. Clin
Cancer Res. 15:5803–5810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzhi Z, Liang T, Yuexia P, Lucy L,
Xiaoting H, Yuan Z and Qin W: Gap junctions enhance the
antiproliferative effect of MicroRNA-124-3p in glioblastoma cells.
J Cell Physiol. 230:2476–2488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cottin S, Gould PV, Cantin L and Caruso M:
Gap junctions in human glioblastomas: Implications for suicide gene
therapy. Cancer Gene Ther. 18:674–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goldberg GS, Bechberger JF and Naus CC: A
pre-loading method of evaluating gap junctional communication by
fluorescent dye transfer. Biotechniques. 18:490–497.
1995.PubMed/NCBI
|
|
15
|
Koreen IV, Elsayed WA, Liu YJ and Harris
AL: Tetracycline-regulated expression enables purification and
functional analysis of recombinant connexin channels from mammalian
cells. Biochem J. 383:111–119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su J, Cai M, Li W, Hou B, He H, Ling C,
Huang T, Liu H and Guo Y: Molecularly targeted drugs plus
radiotherapy and temozolomide treatment for newly diagnosed
glioblastoma: A meta-analysis and systematic review. Oncol Res.
24:117–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng L, Ng L, Ozawa T and Stella N:
Quantitative analyses of synergistic responses between cannabidiol
and DNA-damaging agents on the proliferation and viability of
glioblastoma and neural progenitor cells in culture. J Pharmacol
Exp Ther. 360:215–224. 2017. View Article : Google Scholar
|
|
18
|
Autsavapromporn N, Suzuki M, Funayama T,
Usami N, Plante I, Yokota Y, Mutou Y, Ikeda H, Kobayashi K,
Kobayashi Y, et al: Gap junction communication and the propagation
of bystander effects induced by microbeam irradiation in human
fibroblast cultures: The impact of radiation quality. Radiat Res.
180:367–375. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lawrence TS, Rehemtulla A, Ng EY, Wilson
M, Trosko JE and Stetson PL: Preferential cytotoxicity of cells
transduced with cytosine deaminase compared to bystander cells
after treatment with 5-flucytosine. Cancer Res. 58:2588–2593.
1998.PubMed/NCBI
|
|
20
|
Zhang Y, Tao L, Fan L, Peng Y, Yang K,
Zhao Y, Song Q and Wang Q: Different gap junction-propagated
effects on cisplatin transfer result in opposite responses to
cisplatin in normal cells versus tumor cells. Sci Rep. 5:125632015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Wang X, Wang Q, Ge H and Tao L:
Propofol depresses cisplatin cytotoxicity via the inhibition of gap
junctions. Mol Med Rep. 13:4715–4720. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murphy SF, Varghese RT, Lamouille S, Guo
S, Pridham KJ, Kanabur P, Osimani AM, Sharma S, Jourdan J, Rodgers
CM, et al: Connexin 43 inhibition sensitizes chemoresistant
glioblastoma cells to temozolomide. Cancer Res. 76:139–149. 2016.
View Article : Google Scholar :
|
|
23
|
Gielen PR, Aftab Q, Ma N, Chen VC, Hong X,
Lozinsky S, Naus CC and Sin WC: Connexin43 confers Temozolomide
resistance in human glioma cells by modulating the mitochondrial
apoptosis pathway. Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Naiki-Ito A, Asamoto M, Naiki T, Ogawa K,
Takahashi S, Sato S and Shirai T: Gap junction dysfunction reduces
acetaminophen hepatotoxicity with impact on apoptotic signaling and
connexin 43 protein induction in rat. Toxicol Pathol. 38:280–286.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kameritsch P, Pogoda K and Pohl U:
Channel-independent influence of connexin 43 on cell migration.
Biochim Biophys Acta. 1818:1993–2001. 2012. View Article : Google Scholar
|
|
26
|
Grond S and Sablotzki A: Clinical
pharmacology of tramadol. Clin Pharmacokinet. 43:879–923. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Edmondson MA, Duran SH, Boothe DM, Stewart
AJ and Ravis WR: Pharmacokinetics of tramadol and its major
metabolites in alpacas following intravenous and oral
administration. J Vet Pharmacol Ther. 35:389–396. 2012. View Article : Google Scholar
|
|
28
|
Li C, Chen SQ, Chen BX, Huang WQ and Liu
KX: The antinociceptive effect of intrathecal tramadol in rats: The
role of alpha 2-adrenoceptors in the spinal cord. J Anesth.
26:230–235. 2012. View Article : Google Scholar
|
|
29
|
Xia M, Tong JH, Zhou ZQ, Duan ML, Xu JG,
Zeng HJ and Wang SH: Tramadol inhibits proliferation, migration and
invasion via α2-adrenoceptor signaling in breast cancer cells. Eur
Rev Med Pharmacol Sci. 20:157–165. 2016.
|
|
30
|
Sheikholeslami B, Gholami M, Lavasani H
and Rouini M: Evaluation of the route dependency of the
pharmacokinetics and neuro-pharmacokinetics of tramadol and its
main metabolites in rats. Eur J Pharm Sci. 92:55–63. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pergolizzi JV Jr, Taylor R Jr and Raffa
RB: Extended-release formulations of tramadol in the treatment of
chronic pain. Expert Opin Pharmacother. 12:1757–1768. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leppert W and Mikolajczak P: Analgesic
effects and assays of controlled-release tramadol and
o-desmethyltramadol in cancer patients with pain. Curr Pharm
Biotechnol. 12:306–312. 2011. View Article : Google Scholar
|
|
33
|
Pan EC, Bohn LM, Belcheva MM, Thomas GE,
Manepalli AN, Mamone JY, Johnson FE and Coscia CJ: Kappa-opioid
receptor binding varies inversely with tumor grade in human
gliomas. Cancer. 83:2561–2566. 1998. View Article : Google Scholar
|
|
34
|
Solan JL and Lampe PD: Connexin43
phosphorylation: Structural changes and biological effects. Biochem
J. 419:261–272. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao Y, Yu L, Xu S, Qiu F, Fan Y and Fu G:
Down-regulation of connexin43 gap junction by serum deprivation in
human endothelial cells was improved by (-)-epigallocatechin
gallate via ERK MAP kinase pathway. Biochem Biophys Res Commun.
404:217–222. 2011. View Article : Google Scholar
|
|
36
|
TenBroek EM, Lampe PD, Solan JL, Reynhout
JK and Johnson RG: Ser364 of connexin43 and the upregulation of gap
junction assembly by cAMP. J Cell Biol. 155:1307–1318. 2001.
View Article : Google Scholar
|
|
37
|
Mathews J and Levin M: Gap junctional
signaling in pattern regulation: Physiological network connectivity
instructs growth and form. Dev Neurobiol. 77:643–673. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brockmeyer P, Jung K, Perske C,
Schliephake H and Hemmerlein B: Membrane connexin 43 acts as an
independent prognostic marker in oral squamous cell carcinoma. Int
J Oncol. 45:273–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang A, Hitomi M, Bar-Shain N, Dalimov Z,
Ellis L, Velpula KK, Fraizer GC, Gourdie RG and Lathia JD: Connexin
43 expression is associated with increased malignancy in prostate
cancer cell lines and functions to promote migration. Oncotarget.
6:11640–11651. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Czyz J: The stage-specific function of gap
junctions during tumourigenesis. Cell Mol Biol Lett. 13:92–102.
2008. View Article : Google Scholar
|
|
41
|
Chen MJ, Kress B, Han X, Moll K, Peng W,
Ji RR and Nedergaard M: Astrocytic CX43 hemichannels and gap
junctions play a crucial role in development of chronic neuropathic
pain following spinal cord injury. Glia. 60:1660–1670. 2012.
View Article : Google Scholar : PubMed/NCBI
|
